Michael Andreeff
0000-0002-1144-1958
Publication & Citation Trends
Publications
0 total
Integrated analysis of genomics, molecular responses and outcomes of CBF-AML with FLAG based therapy on a phase 2 trial
Cited by 0
Semantic Scholar
Immunophenotypic changes following menin inhibition in acute myeloid leukemia.
Cited by 1
Semantic Scholar
PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML
Cited by 2
Semantic Scholar
CSF1R-CSF1 axis blockade with axatilimab effectively targets leukemia stem cells and monocytes in AML resistant to BH3 mimetics
Cited by 0
Semantic Scholar
POSTER: AML-517 Characterization of Immunophenotypic Changes Following Menin Inhibition in Acute Myeloid Leukemia
Cited by 0
Semantic Scholar
Extracellular arginine deprivation enhances venetoclax sensitivity in acute myeloidleukemia via mitochondrial fission impairment and apoptotic priming
Cited by 0
Semantic Scholar
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
Cited by 32
Semantic Scholar
Cardio-safe degrader CT-03p degrades MCL-1 and overcomes venetoclax resistance in AML.
Cited by 0
Semantic Scholar
Research Topics
Acute Myeloid Leukemia Research
(859)
Chronic Myeloid Leukemia Treatments
(282)
Protein Degradation and Inhibitors
(222)
Chronic Lymphocytic Leukemia Research
(217)
Acute Lymphoblastic Leukemia research
(176)
Affiliations
Forest Institute
Rutgers, The State University of New Jersey
Dartmouth College
Universidade Federal de Minas Gerais
Roche (Switzerland)